Daraxonrasib & Pan-RAS Inhibitors — PatSnap Eureka
Daraxonrasib & Pan-RAS Inhibitors in KRAS-Mutant Pancreatic Cancer
KRAS mutations drive over 90% of PDAC cases, yet pivotal Phase III data for pan-RAS inhibitors remain critically awaited. Explore the 2026 clinical readout landscape — mutation subtypes, combination strategies, resistance biology, and ctDNA biomarkers — powered by PatSnap Eureka's patent and literature intelligence.
Why KRAS Mutations Make Pancreatic Cancer So Difficult to Treat
Pancreatic ductal adenocarcinoma (PDAC) represents one of oncology's most refractory indications. According to the National Cancer Institute, the five-year survival rate for PDAC sits below 10%. The dominant molecular driver is oncogenic KRAS mutation, present in 80–95% of cases across multiple population-level analyses and single-institution cohort studies. As researchers at the PatSnap life sciences intelligence platform have documented, this creates an unusual situation: a single oncogene drives initiation, progression, and maintenance of nearly all cases.
The KRAS oncoprotein activates at least two major downstream effector cascades: the MAPK/ERK pathway and the PI3K/AKT/mTOR pathway. Researchers at the Netherlands Cancer Institute have highlighted that "targeting single RAS downstream effectors induces adaptive resistance mechanisms" — a finding replicated across multiple independent datasets. This intrinsic adaptive capacity is the central obstacle for monotherapy approaches.
The G12D, G12V, and G12R isoforms — collectively the predominant PDAC variants — have historically resisted direct pharmacological inhibition due to the high GTP affinity and structural characteristics of the RAS GTPase domain. A 2021 paper from the Medical University of South Carolina specifically notes that "while KRAS(G12C) is frequently expressed in lung cancers, it is rare in PDAC. Thus, more broadly efficacious RAS inhibitors are needed for treating KRAS mutant-driven cancers such as PDAC." This gap defines the entire rationale for pan-RAS inhibitor programs including daraxonrasib.
Beyond canonical KRAS, the target landscape includes upstream regulators such as SHP2, downstream effectors ERK1/2 and MEK1/2, the parallel PI3K/AKT/mTOR survival axis, and emerging interactors including RSK1 (identified at Cold Spring Harbor Laboratory) and the hexosamine biosynthetic pathway (HBP) — a metabolic dependency node uniquely relevant to KRAS-mutant PDAC cells. Explore the full target network via PatSnap Eureka's drug intelligence module.
Six Distinct Approaches to Targeting KRAS-Mutant PDAC
From direct pan-RAS small molecules to allosteric biologics and metabolic synthetic lethality — the innovation landscape spans preclinical through Phase II stages.
Direct Pan-RAS Inhibition
The pan-RAS inhibitor compound "cmp4" (University of Milano-Bicocca, 2021) targets multiple steps in the activation and downstream signaling of different Ras mutants and isoforms, binding to an extended Switch II pocket on HRas and KRas to down-regulate intrinsic and GEF-mediated nucleotide dissociation and effector binding. Mathematical modeling confirmed antiproliferative activity across multiple Ras-driven cancer cells including cetuximab-resistant tumors.
PreclinicalAllosteric RAS Interface Targeting
The NS1 Monobody biologic (Medical University of South Carolina, 2021) targets the α4-α5 allosteric interface of KRAS to inhibit RAS self-association and KRAS-mediated oncogenic signaling. This approach is broadly applicable across multiple KRAS mutant isoforms including G12D and G12V — the two most prevalent PDAC subtypes. A 2022 University College Dublin review confirmed that "new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock."
Preclinical → Early ClinicalSHP2 + ERK Dual Inhibition
Two independent groups — the Netherlands Cancer Institute and Universidad Autónoma de Madrid — demonstrated synergistic anti-cancer activity combining RMC-4550 (SHP2 inhibitor) and LY3214996 (ERK inhibitor). Both groups showed in vivo tumor regression in multiple PDAC mouse models with acceptable tolerability. The NCI group provided PET imaging (18F-FDG) evidence of pharmacodynamic target engagement. Retrieved results explicitly state this combination "supports clinical investigation for KRAS mutant pancreatic cancer."
Preclinical (IND-enabling)MEK Inhibitor-Based Regimens
A Phase II trial of selumetinib (MEK1/2 inhibitor, NCT03040986) specifically enrolled KRAS G12R-mutated PDAC patients who had received at least one prior systemic therapy — the first isoform-stratified MAPK inhibitor trial in this indication. The study was premised on preclinical evidence that the G12R isoform is more sensitive to MAPK pathway blockade. A Phase 1 study combining dacomitinib (pan-HER) with PD-0325901 (MEK1/2) enrolled 41 patients including 3 PDAC patients, establishing recommended Phase 2 doses.
Phase I–II ClinicalActive KRAS-Targeting Antibody
The inRas37 antibody (Inha University, 2022) directly targets the intra-cellularly activated GTP-bound form of oncogenic RAS mutation. Combined with the PI3K inhibitor BEZ-235, inRas37 demonstrated synergistic effects in PDAC models, overcoming MAPK pathway reactivation that limits PI3K inhibitor monotherapy. This intrabody or cell-penetrating antibody strategy is distinct from classical anti-EGFR approaches.
PreclinicalPan-RAS + HBP Synthetic Lethality
The Milano-Bicocca group demonstrated that KRAS-mutant PDAC cells exhibit heightened hexosamine biosynthetic pathway (HBP) flux dependency. Inhibition via 2-deoxyglucose or FR054 substantially potentiates pan-RAS inhibitor sensitivity — KRAS-oncogenic PDAC cells become "strongly reliant on HBP for both proliferation and survival." This metabolic synthetic lethality concept represents a novel combinatorial angle not previously prominent in the literature.
Preclinical (in vitro)KRAS-Mutant PDAC: Key Innovation Signals Visualised
Patent and literature data from PatSnap Eureka reveals the distribution of therapeutic modalities, clinical development stages, and combination strategy validation across this dataset.
Combination Strategy Preclinical Validation Depth
SHP2+ERK dual inhibition has the strongest multi-group preclinical validation in this dataset, supported by two independent institutions with in vivo evidence.
Clinical Development Stage by Therapeutic Approach
Most KRAS-mutant PDAC approaches remain in preclinical stages; only MEK inhibitor-based regimens have reached Phase I–II clinical evaluation in this dataset.
Six Mechanistically Grounded Combination Approaches
Resistance to pan-RAS monotherapy is biologically pre-encoded. These combinations address specific adaptive resistance mechanisms identified in the literature.
SHP2 + ERK Dual Inhibition
The most extensively validated combination in this dataset. Two independent groups (Netherlands Cancer Institute, UAM Madrid) demonstrated preclinical superiority over monotherapy. RMC-4550 + LY3214996 showed in vivo efficacy and PET-measurable pharmacodynamic response. This combination "supports clinical investigation for KRAS mutant pancreatic cancer."
Pan-RAS Inhibitor + HBP Inhibition
Inhibiting the hexosamine biosynthetic pathway via FR054 or 2-deoxyglucose renders KRAS-mutant PDAC cells strongly reliant on HBP for both proliferation and survival, substantially potentiating pan-RAS inhibitor effects. This metabolic synthetic lethality concept is novel within the retrieved dataset and represents an underexploited IP white space.
KRAS Antibody + PI3K Inhibition
The inRas37 antibody combined with BEZ-235 (dual PI3K/mTOR inhibitor) overcomes MAPK pathway reactivation that limits PI3K inhibitor monotherapy in PDAC — directly addressing a known adaptive resistance mechanism identified in the CRISPR-based KRAS dispensability studies from MIT/Dana-Farber.
KRAS/SOS1 + MEK + PI3K Triple Combination
Rostock University (2022) demonstrated that BI-3406 (KRAS::SOS1 inhibitor) or sotorasib, combined with trametinib (MEK1/2) and/or buparlisib (PI3K), showed synergistic cytotoxicity in a panel of 7 PDAC cell lines. Whole transcriptomic analysis was used to characterize combination mechanisms.
Clinical Trial Data & Patent Assignee Landscape
From Phase I dose-escalation studies to the only isoform-selected Phase II trial in KRAS G12R-mutant PDAC — here is what the dataset contains.
| Study / Program | Agents | Phase | Patient Population | Key Outcome |
|---|---|---|---|---|
| NCT03040986 UC Davis, 2021 | Selumetinib (MEK1/2) | Phase II | KRAS G12R-mutant advanced PDAC; ≥1 prior therapy; 75 mg BID | First isoform-stratified MAPK inhibitor trial in PDAC; BOR primary endpoint |
| Dacomitinib + PD-0325901 Erasmus MC, 2020 | Pan-HER + MEK1/2 | Phase I | 41 patients (CRC, NSCLC, PDAC); 3 PDAC patients enrolled | RP2D established; 8/41 patients had dose-limiting toxicities |
| Dinaciclib + MK-2206 Johns Hopkins, Phase I | CDK inhibitor + AKT inhibitor | Phase I | 39 advanced/metastatic previously treated PDAC patients | No objective responses; 4 patients (10%) achieved stable disease; MTD established |
| Cobimetinib + Gemcitabine Univ. of Miami, 2021 | MEK + Chemotherapy | Phase I (exploratory) | 13 KRAS G12X-mutant PDAC patients (G12D, G12V, G12R) | Activity noted in G12R-mutated patients who had failed multiple prior chemotherapy regimens |
Patent Assignee Landscape
Takeda Pharmaceutical Company Limited
Three active patents (US, WO, EP jurisdictions, 2018–2021) covering KRAS mutation status as a predictive biomarker for CDC7 inhibitor response in pancreatic cancer. Further refines predictions using combined TP53/p16Ink4 co-mutation status. The most concentrated commercial IP on KRAS-biomarker methodology in this dataset. Legal status is active across multiple jurisdictions.
CDC7 Inhibitor Companion DiagnosticAmgen Inc.
Multiple active patents (EP, HU, RS, ES jurisdictions) on K-RAS mutations in the context of anti-EGFR antibody therapy and predictive diagnostics. Note: these are directed primarily at colorectal cancer indications rather than PDAC — an important distinction for IP freedom-to-operate analyses in the pancreatic cancer space. Explore the full patent analytics landscape via PatSnap.
Anti-EGFR Companion DiagnosticsMap the full KRAS-mutant PDAC IP landscape
Identify white spaces, active assignees, and freedom-to-operate signals across pan-RAS inhibitor programs.
What the 2026 Pivotal Data Landscape Means for Drug Developers
Isoform selection is a critical trial design variable. Retrieved clinical data from the selumetinib G12R trial and cobimetinib + gemcitabine in G12R patients demonstrate that KRAS mutation subtype stratification — not merely KRAS-mutant status — is required for meaningful signal detection in PDAC trials. Pan-RAS inhibitor pivotal trials should incorporate subtype-stratified analyses to detect differential efficacy signals across G12D, G12V, and G12R populations. The WHO's global cancer research framework increasingly supports biomarker-stratified trial designs.
Resistance to monotherapy is biologically pre-encoded. The CRISPR-based finding that PI3K-dependent MAPK bypass emerges upon complete KRAS elimination, combined with SHP2/ERK data showing adaptive resistance upon single-pathway inhibition, strongly signals that pan-RAS monotherapy approval pathways face an intrinsic resistance ceiling. Combination regimens will likely be required for durable clinical benefit — a conclusion supported by NIH-funded mechanistic studies and multiple independent academic groups.
ctDNA is a validated pharmacodynamic tool. Multiple independent academic groups have demonstrated that longitudinal ctDNA monitoring predicts treatment response, recurrence, and overall survival in PDAC. This supports its incorporation as a co-primary or secondary endpoint in Phase III pan-RAS inhibitor trials to enable early futility analysis and response-adaptive design. The PatSnap life sciences intelligence platform tracks ctDNA biomarker patent activity across all major oncology indications.
The HBP synthetic lethality axis and RSK1/NF1 network represent underexploited IP white spaces. Neither the hexosamine pathway sensitization strategy nor the RSK1/NF1 KRAS interactor network appears to be covered by patents in the retrieved dataset, representing potential first-mover IP opportunities for organizations seeking to differentiate combination strategies from established MEK/PI3K approaches. Organizations can verify current IP coverage via PatSnap's patent analytics tools.
Commercial IP in KRAS-mutant PDAC diagnostics is concentrated but less contested than KRAS G12C in lung cancer. Takeda (CDC7 biomarker) and Amgen (anti-EGFR companion diagnostics) hold the primary commercial IP in this dataset. Academic groups drive the preponderance of mechanistic and translational innovation. Drug developers evaluating pan-RAS inhibitor licensing should note that the companion diagnostic IP landscape for PDAC is materially less contested, potentially facilitating broader biomarker integration in pivotal trial designs. Explore enterprise data access options at PatSnap Open API.
Daraxonrasib & Pan-RAS Inhibitors in KRAS-Mutant PDAC — Key Questions Answered
The G12D substitution is the most prevalent subtype, present in approximately 40% of KRAS-mutant PDAC, followed by G12V (~30%) and G12R (~15–20%), as documented in both population-level analyses and single-institution cohort studies.
The G12D, G12V, and G12R isoforms have historically resisted direct pharmacological inhibition due to the high GTP affinity and structural characteristics of the RAS GTPase domain.
The pan-RAS inhibitor compound cmp4 targets multiple steps in the activation and downstream signaling of different Ras mutants and isoforms. The mechanism involves binding to an extended Switch II pocket on HRas and KRas, inducing conformational changes that down-regulate intrinsic and GEF-mediated nucleotide dissociation and exchange and effector binding.
Two independent groups — the Netherlands Cancer Institute and the Universidad Autónoma de Madrid — demonstrated synergistic anti-cancer activity with combined SHP2 and ERK inhibition using RMC-4550 and LY3214996, respectively, with in vivo tumor regression in multiple PDAC mouse models and PET imaging evidence of pharmacodynamic target engagement. Retrieved results explicitly state this combination supports clinical investigation for KRAS mutant pancreatic cancer.
A CRISPR-based study from MIT/Dana-Farber demonstrated that nearly all KRAS-deficient cells exhibit phosphoinositide 3-kinase (PI3K)-dependent mitogen-activated protein kinase (MAPK) signaling and induced sensitivity to PI3K inhibitors. This means even complete KRAS elimination activates PI3K-dependent compensatory MAPK signaling, suggesting that pan-RAS monotherapy will likely require combination strategies to achieve durable responses.
Multiple independent academic groups have demonstrated that longitudinal ctDNA monitoring predicts treatment response, recurrence, and overall survival in PDAC. Longitudinal cfKRAS tracking was demonstrated to predict recurrence-free survival and overall survival following curative resection, supporting its incorporation as a co-primary or secondary endpoint in Phase III pan-RAS inhibitor trials to enable early futility analysis and response-adaptive design.
Still have questions about KRAS-mutant PDAC drug development? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka NowAccelerate Your Pan-RAS Inhibitor Research in PDAC
Join 18,000+ innovators already using PatSnap Eureka to navigate KRAS oncology patent landscapes, identify combination strategy white spaces, and track 2026 pivotal readouts in real time.
References
- Targeting KRAS in Pancreatic Cancer — Conway Institute, University College Dublin, 2022
- The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells — University of Milano-Bicocca, 2021
- Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor — University of Milano-Bicocca, 2021
- Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer — Netherlands Cancer Institute / Oncode Institute, 2022
- Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma — Universidad Autónoma de Madrid, 2021
- Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis — Medical University of South Carolina, 2021
- Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma — UC Davis Comprehensive Cancer Center, 2021
- Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer — Erasmus MC Cancer Institute, 2020
- Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies — Sylvester Comprehensive Cancer Center, University of Miami, 2021
- Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer — Inha University, 2022
- Survival of pancreatic cancer cells lacking KRAS function — MIT / Dana-Farber Cancer Institute, 2017
- Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer — Cold Spring Harbor Laboratory, 2021
- Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer — Cold Spring Harbor Laboratory, 2020
- Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer — Jichi Medical University, 2019
- Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer — Freiburg University Medical Center, 2021
- KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma — INSERM UMR 1037, University of Toulouse, 2016
- KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation? — Monash University, 2022
- Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines — Rostock University Medical Center, 2022
- Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer — Hokkaido University, 2021
- A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer — Johns Hopkins University / Sidney Kimmel
- National Cancer Institute — Cancer Statistics and PDAC Overview
- National Institutes of Health — KRAS Oncology Research Programs
- World Health Organization — Global Cancer Research Framework
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.